Swedish Orphan Biovitrum AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOVF research report →
About the company
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin).
- CEO
- Guido Oelkers
- IPO
- 2021
- Employees
- 1,895
- HQ
- Solna, SE
Price Chart
- Market Cap
- $16.60B
- P/E
- 180.75
- P/S
- 5.72
- P/B
- 4.10
- EV/EBITDA
- 16.24
- Div Yield
- 0.00%
- Gross Margin
- 44.17%
- Op Margin
- 29.56%
- Net Margin
- 3.18%
- ROE
- 2.41%
- ROIC
- 12.10%
- Revenue
- $28.17B · 8.22%
- Net Income
- $476.80M · -87.73%
- EPS
- $1.39 · -87.77%
- Op Income
- $8.03B
- FCF YoY
- 93.99%
- 52W High
- $48.00
- 52W Low
- $28.93
- 50D MA
- $46.88
- 200D MA
- $38.79
- Beta
- 0.29
- Avg Volume
- 8
Get TickerSpark's AI analysis on BIOVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BIOVF coverage
Recent articles, reports, and earnings notes.
No research on BIOVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOVF report →Similar companies
Peers in the same neighborhood.